PDCD1 and esophageal cancer: Therefore, the aim of this study was to establish an effective model for predicting the ORR of esophageal cancer patients after neoadjuvant TP (platinum + taxol) regimen combine with PD-1 inhibitors (Pembrolizumab, Camrelizumab, Tislelizumab or Sintilimab).